GET DAILY SIGNALSWhy Is Pulmonx Corporation (LUNG) Stock Up +20.24% Today?
Key Takeaways
- Pulmonx Corporation (LUNG) shares climbed about 20% on Thursday, extending a sharp two-session rally to roughly $3.03 from a prior close of $2.52.
- Primary catalyst: A post-earnings momentum run following better-than-expected third-quarter 2026 results released after Tuesday's close, headlined by a return to year-over-year revenue growth.
- Secondary driver: Wall Street analysts responded favorably, with Stifel raising its price target to $4 from $2.50 and Canaccord setting a $5 target.
- Broader context: The move reflects continued follow-through buying in a thinly traded small-cap medical-device name after the prior session's roughly 27% surge.
- What traders are watching next: Fourth-quarter execution, the resumption of China shipments, and upcoming investor conference appearances in November.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages for deeper analysis.
- Interested in automated trading signals? Review the latest Trending AI Robots to see which strategies are performing best in current conditions.
Opening Summary
Pulmonx Corporation (LUNG), a Redwood City, California-based medical-technology company specializing in minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease (COPD), extended its rally on Thursday. The company's flagship Zephyr Endobronchial Valve is used to treat patients with severe lung disease who remain symptomatic despite medical management. Shares advanced roughly 20.24%, or about $0.51, to trade near $3.03, up from the prior session's close of $2.52, as investors continued to digest a stronger-than-expected quarterly report and a wave of supportive analyst commentary.
Earnings Beat and Return to Growth
The dominant catalyst behind the two-day move was Pulmonx's third-quarter 2026 financial results, reported after the market closed on Tuesday. The company posted revenue of $22.8 million, a 6% increase from $21.5 million a year earlier and ahead of analyst expectations of roughly $21.9 million. Notably, the quarter marked Pulmonx's first return to year-over-year revenue growth in both its U.S. and international businesses since the current management team rejoined the company.
The bottom line also improved markedly. Pulmonx reported a GAAP net loss of $8.4 million, or $0.19 per share, narrowing from a loss of $0.34 per share in the prior-year period and beating the consensus estimate of a $0.26 loss. Adjusted EBITDA loss narrowed by nearly 60% to $3.5 million, while gross margin improved to 76% from 75%. Management also reiterated its full-year 2026 revenue guidance of $90 million to $92 million, reinforcing confidence in the commercial turnaround.
Analyst Support and Price-Target Increases
The fundamental beat was amplified by fresh analyst endorsements. Stifel raised its price target on LUNG to $4.00 from $2.50 while maintaining a Buy rating, and Canaccord Genuity reiterated its Buy rating with a $5.00 target. The upgrades underscored the view that Pulmonx's rebuilt U.S. sales force and disciplined expense management are translating into accelerating commercial traction. Management noted it added eight new U.S. treating centers during the quarter and has substantially filled its open sales territories.
Market Context and Trading Activity
Trading in LUNG has been exceptionally heavy during the rally, with the prior session's volume running well into the millions of shares versus a far lower typical daily average — a clear sign of elevated conviction among buyers reacting to the earnings surprise. The stock has now broken decisively above its 50-day moving average near $2.02 and its 200-day moving average near $1.65, marking a meaningful technical breakout for a small-cap name with a market capitalization measured in the low hundreds of millions of dollars.
The move is largely company-specific rather than a broad sector rotation, though it aligns with a generally favorable backdrop for medical-device equities. The two-day surge also reflects the outsized percentage moves typical of low-priced, thinly traded stocks, where even moderate buying pressure can produce pronounced price swings.
What Comes Next for LUNG
Looking ahead, investors will monitor whether Pulmonx can sustain its return to growth through the fourth quarter, which is expected to carry the company's full-year revenue toward the low $90 million range. The resumption of shipments to its Chinese distributor, anticipated by early next year, represents a potential incremental tailwind, though management has characterized China as a relatively small and lumpy contributor to overall revenue. Upcoming appearances at the Canaccord Genuity MedTech Forum and the Stifel Healthcare Conference in November could provide additional visibility into commercial execution and the company's 2027 outlook.
Risks remain. The company is still unprofitable, continues to burn cash, and relies heavily on a single flagship product family. Insider selling has also been a recurring theme in recent quarters. As such, the sustainability of the current rally will likely hinge on evidence that revenue growth and margin improvement persist into 2027.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to evaluate. Explore the page to see which automated strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG in upward trend: price rose above 50-day moving average on October 28, 2026
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +29.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.761) is normal, around the industry mean (3.824). P/E Ratio (-2.191) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement